Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent anion-selective channel 1 (VDAC1) is a 19-strand beta-barrel protein that serves as the primary "gatekeeper" of the outer mitochondrial membrane (OMM) [9, 12, 15]. It functions as a critical conduit for the exchange of ions and metabolites—most notably ATP and ADP—between the mitochondria and the cytoplasm, thereby regulating cellular energy homeostasis and bioenergetics [2, 9, 20]. Beyond its role in metabolism, VDAC1 is central to the intrinsic pathway of apoptosis; under stress or specific signaling, VDAC1 can undergo oligomerization to form large pores that facilitate the release of pro-apoptotic factors like cytochrome c into the cytosol [1, 5, 7]. In many cancers, VDAC1 is significantly overexpressed, where it associates with proteins such as hexokinase and Bcl-2 to promote a high glycolytic rate and provide resistance to cell death [12, 13, 20]. Conversely, in neurodegenerative diseases like Alzheimer's and Parkinson's, pathological VDAC1 oligomerization and calcium dysregulation contribute to premature neuronal loss [15, 18]. Therapeutic strategies involving VDAC1 include small molecules like erastin that induce ferroptotic cell death in tumors, and inhibitors like VBIT-4 that prevent oligomerization to protect cells from neurodegeneration and inflammation [7, 18, 19].
Modulation of VDAC1 channel gating, oligomerization, or protein-protein interactions (e.g., with HK-II or Bcl-2) to regulate mitochondrial metabolite exchange and the release of pro-apoptotic factors.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion-selective channel 1 (VDAC1).